Pluristem Therapeutics Inc ,is a leading developer of placenta-based cell therapies.

Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) is a leading developer of placenta-based cell therapies. The company’s patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an off-the-shelf product that requires no tissue matching or immune-suppression treatment prior to administration. PLX-PAD comprehensive clinical development plan has been recognized by both the EMA and FDA, targeting a sub-population of 20-million patients of Peripheral Artery Disease (PAD) market.

Data from two Phase I clinical trials indicate that Pluristem’s first PLX product, PLX-PAD, is safe and potentially effective for the treatment of end stage PAD. Pluristem’s pre-clinical animal models have demonstrated PLX cells are also potentially effective in nerve pain and muscle damage when administered locally and in inflammatory bowel disease, MS and stroke when administered systemically. Pluristem has a strong patent portfolio, company-owned GMP certified manufacturing and research facilities, strategic relationships with major research institutions and a seasoned management team.

Pluristem’s Mission, Vision and Values
Pluristem Therapeutics Inc. is a bio-therapeutics Company, dedicated to giving patients a better chance to recover from a variety of severe degenerative, malignant and autoimmune disorders through the commercialization of unrelated donor-patient (allogeneic) stem cell therapy products.

Pluristem has made the strategic decision to work only with adult stem cells, purified from the placenta after birth and, therefore, not subject to ethical or religious controversy.

Pluristem’s vision is one of commitment, integrity, teamwork, inspiration, novelty and quality. We lead by example and expect others to maintain these high standards. As individuals and as an organization we strive to perform to our maximum abilities for the common good of ourselves, our shareholders’ and those who need and use our products.

Commitment – We are committed to developing novel therapeutics aimed at improving our patient’s health and quality of life. We are a Company committed to an atmosphere of creative discovery and of nurturing our core technologies within a framework of focused strategic directions.

Integrity – We aim to maintain the highest scientific and ethical standards and expect those standards to be evident in the quality of all of our products, programs and processes. In turn, we believe that by maintaining these standards, they will translate into enhanced shareholder value.

Teamwork – It is our responsibility to build and maintain a successful, winning team. We have learned this is accomplished by providing excellent leadership, organization and procedures and by hiring and cultivating individuals who are highly capable, committed and cooperative, and who participate and communicate well.

Inspiration- With a deep understanding of the patient’s needs on the one hand, and sound, innovative management on the other, we will create the needed inspiration for finding new and original solutions.

Novelty – We believe we have built and will continue to build an innovative Company that will provide superior products to a greater number of patients than what currently available technology is able to provide.

Quality (doing it right) – We integrate quality into our management processes, organizational structure and corporate culture. We design our Company processes to fulfill requirements, prevent failures and reinforce excellence. We set our expectations high, dedicate sufficient resources and work energetically to meet them.

We consider our shareholders and partners to be a part of our team. We will build and sustain our public partnership based on honesty, trust and integrity. We will communicate regularly with our shareholders and partners and remain fully compliant with applicable regulations, policies and laws.



Both comments and pings are currently closed.

Comments are closed.